Drug development for neglected diseases

Field test for various open innovation initiatives

Abstract

There is a lack of sufficient research and development regarding diseases almost exclusively affection poor countries. One reason is seen in the financially weak demand, which can not sufficiently stimulate the complex commercialized product development. In recent years, national and international measures have been discussed and partly been implemented to attenuate the systemic problem of the patent-based innovation process, at least for poverty-related diseases. Some Stakeholders are testing how the idea of open source software development – the collaboration of volunteers generate products that are not owned by a company – can be transferred to drug development. They open different elements of the pharmacological innovation process for sharing and further drug development. Partly they call this Open Innovation. The article presents relevant initiatives.

Published
15.08.2017
How to Cite
GERLINGER, K. Drug development for neglected diseases. TATuP - Zeitschrift für Technikfolgenabschätzung in Theorie und Praxis, v. 26, n. 1-2, p. 37-42, 15 Aug. 2017.